Търсене на изпитвания

AI · Cancer

Намерени 1,993 изпитвания за "Cancer" Стр. 95 от 100

Активно (без набиране) Фаза 2

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

Brain and Central Nervous System Tumors

RATIONALE: In this study a combination of anti-cancer drugs (chemotherapy) is used to treat brain tumors in young children. Using chemotherapy gives the brain more time to develop before radiation is given. The chemotherapy in this study includes the drug methotrexate. This drug was an important part of the two clinical trials which resulted in the best survival results for children less than 3 years of age with medulloblastoma. Most patients treated on this trial will also receive radiation which is carefully targeted to the area of the tumor. This type of radiation (focal conformal or proton beam radiotherapy) may result in fewer problems with thinking and learning than radiation to the whole brain and spinal cord. PURPOSE: This clinical trial is studying how well giving combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed central nervous system tumors.

Начало: 17.12.2007 Край: 01.04.2026 Възраст: до 5 г. Лечение

Australia, United States St. Jude Children's Research Hospital NCT00602667

Активно (без набиране) Фаза 3

Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

Stage I Kidney Wilms Tumor Stage II Kidney Wilms Tumor Stage III Kidney Wilms Tumor

This phase III trial is studying vincristine, dactinomycin, and doxorubicin with or without radiation therapy or observation only to see how well they work in treating patients undergoing surgery for newly diagnosed stage I, stage II, or stage III Wilms' tumor. Drugs used in chemotherapy, such as vincristine, dactinomycin, and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors.Giving these treatments after surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery, the tumor may not need additional treatment until it progresses. In this case, observation may be sufficient.

Начало: 06.11.2006 Край: 31.03.2026 Възраст: до 29 г. Лечение

Australia, Canada, Israel +4 Children's Oncology Group NCT00352534

Активно (без набиране) Фаза 2

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

Lymphoproliferative Disorder HHV-8 Malignancy HIV

This study will gain information about a rare disorder called KSHV-associated multicentric Castleman's disease (MCD). KSHV, a virus, causes several kinds of cancer, including some forms of MCD. KSHV stands for the Kaposi's sarcoma herpes virus, also called human herpes virus-8, or HHV-8. Researchers want to understand the biology of KSHV-MCD to identify how this disease causes illness and to find ways to treat it. There is no standard therapy effective for all cases of KSHV-MCD. The disease is often fatal, and about half the people who have it die within 2 years of diagnosis. Participants ages 18 and older may be eligible for this study. Participation entails more drawing of blood and having repeated tumor biopsies than if patients received treatment in a non-research setting. Researchers would like to learn more about the relationship of KSHV and Castleman's disease symptoms, and they want to obtain at least three biopsies in this study. There are some side effects of experimental therapy that participants may take for KSHV-MCD. Zidovudine, or Retrovir(R), is used at a high dose. It is given orally or through a vein, four times daily, for 7 days or longer. Zidovudine can cause nausea, vomiting, decreased bone marrow function, and decreased blood counts. Combined with valganciclovir, or Valcyte(TM), it is likely to be more toxic to bone marrow. Valganciclovir can cause problems with bone marrow function, leading to low blood counts, sterility, and defects in a fetus. Combined with zidovudine, valganciclovir may cause more toxicity to the bone marrow. It is given twice daily for 7 days or longer. Bortezomib, or Velcade(TM), is given for a few seconds by a rapid push through a needle into the vein. It is given twice weekly for four doses and then stopped for 1 week. Bortezomib can sometimes cause low blood pressure; it also can cause gastrointestinal problems and a low blood platelet count. Rituximab and liposomal doxorubicin are drugs given by a catheter into a vein. Interferon-alpha is given by injection into the skin. Those drugs are not experimental, but their use in Castleman's disease is experimental. Some participants may be treated with a combination of chemotherapy followed by interferon-alpha. Interferon-alpha is infected into the skin by a needle. The natural form of interferon is produced by the body and helps to control viral infections. KSHV decreases the effect of the body's interferon, and the researchers want to see if giving higher doses of interferon will help to control KSHV infection. A positron emission tomography (PET) scan, for research purposes only, may be done up to three times a year. A radioactive sugar molecule called fluorodeoxyglucose, or FDG, is used. It is believed that activated lymphocytes that may be found in participants' disease might use more FDG because these cells burn more glucose fuel. This study may or may not have a direct benefit for participants. However, detailed assessments made throughout the study may provide information to help the doctors treat KSHV-MCD better. ...

Начало: 28.10.2004 Край: 01.10.2026 Възраст: от 18 г.

United States National Cancer Institute (NCI) NCT00092222

Активно (без набиране) Фаза 3

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Melanoma (Skin)

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not yet known whether treatment with interferon alfa is more effective than observation alone for stage II or stage III melanoma that has been completely removed surgically. PURPOSE: This randomized phase III trial is studying high dose interferon alfa to see how well it works compared to observation only in treating patients with stage II or stage III melanoma that has been completely removed by surgery.

Начало: 25.03.1999 Край: 01.12.2026 Възраст: от 18 г. Лечение

Australia, Canada, South Africa +1 ECOG-ACRIN Cancer Research Group NCT00003641

Активно (без набиране)

Optimization and Standardization of Single-Port Robotic Transanal Minimally Invasive Surgery for Rectal Tumor Excision

Rectal Neoplasms Rectal Cancer Patients Rectal Benign Lesions

Title Case Summary: "This study evaluates the safety, feasibility, and short-term clinical outcomes of a new surgical approach called Single-Port (SP) Robotic Transanal Minimally Invasive Surgery (SPR TAMIS) for treating rectal tumors." Content: Transanal Minimally Invasive Surgery (TAMIS) is a standard technique for treating early-stage rectal tumors. However, traditional TAMIS often faces challenges such as restricted vision and instrument crowding in the narrow rectum. The purpose of this study is to establish a standardized surgical procedure using a single-port robotic platform, which provides better flexibility and visualization. The investigators will analyze real-world clinical cases and surgical videos to assess key outcomes, including the success of tumor resection (R0 resection rate), operative safety, and patient recovery parameters. The study aims to provide clinical evidence for this robotic technique and facilitate its standardized implementation in surgical practice.

Начало: 01.01.2026 Край: 31.12.2029 Възраст: 20–80 г.

Taiwan Jeng-Fu You NCT07522294

Активно (без набиране) Фаза 2

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

Melanoma (Skin Cancer) Unresectable Melanoma Metastatic Melanoma

This is a Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes \[TIL\]) in participants with previously treated advanced melanoma

Начало: 28.11.2025 Край: 01.12.2033 Възраст: 18–70 г. Лечение

Australia, Canada, United Kingdom +1 Iovance Biotherapeutics, Inc. NCT07288203

Активно (без набиране)

Mortality Benefit of Ultrasound for Thyroid Nodules Identified With PET Imaging: Non-Inferiority Emulated Target Trial

Thyroid Nodule (Benign) Thyroid Nodule (Diagnosis) Thyroid Cancer

The investigators hypothesize that all-cause mortality in patients with an incidental thyroid nodule on PET-CT who did not have thyroid ultrasound (the exposure) within 3 months of the PET-CT is non-inferior within a 5% margin to those who have thyroid ultrasound at 7-years. That is, among patients with an incidental thyroid nodule on PET-CT, mortality is no more than 5% larger (in absolute difference) for those who do not have thyroid ultrasound compared to those who do. The investigators will also report mortality differences at landmark timeframes of 1-year, 3-years, 5-years, and 10-years. To estimate group differences in mortality, the investigators will conduct a non-inferiority emulated target trial utilizing clone-censor weighting to address potential immortal time bias introduced by the 3-month grace period. The investigators will adjust for demographic, potential confounder, and mortality risk adjustor factors. The investigators will stratify analyses based on baseline disease severity (estimated 5-year relative survival risk) and disease status (progression, lymph node involvement, other sites of metastases). All subjects will be accrued from the Mass General Brigham healthcare system, which includes two academic medical centers, a specialty head and neck hospital, and multiple community hospitals and numerous community clinics.

Начало: 15.10.2025 Край: 30.06.2026 Възраст: от 18 г.

United States Brigham and Women's Hospital NCT07255482

Активно (без набиране) Фаза 1

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Pancreatic Ductal Adeno Carcinoma Colorectal Cancer Non- Small Cell Lung Cancer (NSCLC) Renal Cell Carcinoma

Trial status: Authorised

Начало: 30.01.2025 Възраст: от 18 г.

France, Germany, Italy +1 Kura Oncology Inc. 2024-513285-19-00

Активно (без набиране) Фаза 1

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Pancreatic Ductal Adenocarcinoma Non-small Cell Lung Cancer Colorectal Cancer Advanced Solid Tumor +1

The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combination with other treatments. The study will have 2 parts: monotherapy dose escalation and dose optimization. The study is expected to last up to approximately 5 years.

Начало: 21.10.2024 Край: 01.01.2030 Възраст: от 18 г.

Belgium, China, France +6 Eli Lilly and Company NCT06607185

Активно (без набиране) Фаза 1

A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors

Cancer-Neoplasms

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary clinical activity of RO7567132 as single agent and in combination with atezolizumab. The study will enroll adult participants with selected locally advanced and/or metastatic solid tumors for whom standard therapy does not exist, or has proven to be ineffective or intolerable.

Начало: 16.09.2024 Край: 10.08.2027 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +2 Hoffmann-La Roche NCT06537310

Активно (без набиране) Фаза 1/2

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

MSI-H/dMMR Gastroesophageal-junction Cancer MSI-H/dMMR Gastric Cancer

This study will investigate the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) in combination with pembrolizumab in in microsatellite instability-high/Defective mismatch repair (MSI-H/dMMR) locally advanced unresectable or metastatic gastric /GEJ adenocarcinomas.

Начало: 31.08.2024 Край: 01.08.2027 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +11 Servier Bio-Innovation LLC NCT06116136

Активно (без набиране) Фаза 1

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Advanced Solid Tumor Metastatic Solid Tumor Prostate Cancer Pancreas Cancer +3

This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors.

Начало: 13.08.2024 Край: 30.11.2027 Възраст: от 18 г.

Spain, United Kingdom, United States MOMA Therapeutics NCT06545942

Активно (без набиране)

Evaluation of Improved Onboard Patient Imaging

Head and Neck Cancer Breast Cancer Upper Gastrointestinal Cancer Lung Cancer +1

The primary objective of radiation therapy is to deliver a therapeutic dose of radiation precisely to the target while minimizing exposure to healthy surrounding tissues. Image-guided radiation therapy (IGRT) involves acquiring cone beam computed tomography (CBCT) scans just before or during treatment sessions. By comparing the CBCT images with the reference images from the treatment planning process, clinicians can make necessary adjustments to ensure precise targeting and account for any changes that may have occurred since the initial planning. Conventional CBCT technology is, however, limited by several factors including long acquisition times that result in motion artifacts in the image, smaller fields of view that limit the volume of anatomy that can be imaged, poor image quality that limits soft tissue visibility, and artifacts created by dense metal implants. This study will evaluate a novel CBCT imaging solution ("HyperSight") that has the potential to address the challenges of conventional CBCT.

Начало: 10.07.2024 Край: 01.12.2026 Възраст: от 18 г.

United States Varian, a Siemens Healthineers Company NCT06187103

Активно (без набиране)

The OPBC-07/microNAC Study

Breast Cancer

The aim of this multicenter retrospective cohort study is to determine the safety of omission of axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy.

Начало: 15.05.2024 Край: 01.06.2025 Възраст: 18–100 г.

Argentina, Australia, Brazil +23 University Hospital, Basel, Switzerland NCT06529302

Активно (без набиране) Фаза 2

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Pancreatic Cancer

This is a Phase 2, multicenter, open-label, 3-arm, randomized, parallel group study to evaluate the efficacy and safety of TTX-030 with or without budigalimab in combination with chemotherapy (gemcitabine + nab-paclitaxel) in subjects with metastatic PDAC who did not have prior treatment for metastatic disease and are eligible to receive gemcitabine and nab-paclitaxel chemotherapy as SOC.

Начало: 25.03.2024 Край: 01.06.2027 Възраст: от 18 г. Лечение

Australia, France, Italy +4 Trishula Therapeutics, Inc. NCT06119217

Активно (без набиране) Фаза 1

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Metastatic Solid Tumor Recurrent Solid Tumor Advanced Solid Tumor Urinary Bladder Neoplasm +10

The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.

Начало: 05.03.2024 Край: 01.03.2027 Възраст: от 18 г. Лечение

Australia, Belgium, China +4 Eli Lilly and Company NCT06238479

Активно (без набиране) Фаза 2

A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

Non-Small Cell Lung Cancer Renal Cell Carcinoma Melanoma

The purpose of this study is to evaluate participant preference for coformulated hyaluronidase/pembrolizumab pembrolizumab (+) berahyaluronidase alfa \[MK-3475A\] administered subcutaneously (SC) over pembrolizumab \[MK-3475\] administered intravenously (IV) in participants with multiple tumor types. There will be no hypothesis testing in this study.

Начало: 26.12.2023 Край: 15.02.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Chile +7 Merck Sharp & Dohme LLC NCT06099782

Активно (без набиране) Фаза 1

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

Advanced Cancer Advanced Malignancies Bladder Cancer Cervical Cancer +8

The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.

Начало: 13.10.2023 Край: 01.03.2026 Възраст: от 18 г. Лечение

Australia, Taiwan, United States Arcus Biosciences, Inc. NCT05891171

Активно (без набиране)

Real World Registry for Use of the Ion Endoluminal System

Lung Cancer Multiple Pulmonary Nodules Lung Neoplasms Respiratory Tract Neoplasms +5

The primary objective of this study is to evaluate the performance of the Ion Endoluminal System with real-world use for pulmonary lesion localization or biopsy.

Начало: 21.09.2023 Край: 01.08.2028 Възраст: от 18 г.

United States Intuitive Surgical NCT06004440

Активно (без набиране) Фаза 1

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Non-Small Cell Lung Cancer Pancreatic Cancer Locally Advanced Solid Tumor Metastatic Solid Tumor

This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1 gene fusions or selected HER3 mutations.

Начало: 06.09.2023 Край: 01.03.2031 Възраст: от 18 г. Лечение

Australia Hummingbird Bioscience NCT05919537

1 … 93 94 95 96 97 … 100